Peptide Library

Human study PLS-00192

Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.

Case-control study · 62 participants enrolled · not included in the assessments (wrong compound)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Peptidomic Identification of Serum Peptides Diagnosing Preeclampsia.primary · PloS one · 2013-06-19 · PMID 23840341 · DOI

Design and participants

Design
Case-control study
Population
Pregnant women with preeclampsia and healthy pregnant controls
Conditions
Preeclampsia
Planned enrollment (registry)
Not reported
Enrolled
62
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Serum peptides can accurately discriminate active preeclampsia. A 19-peptide panel measured by mass spectrometry could aid prediction of preeclampsia or its differential diagnosis from chronic hypertension.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta-4 was not administered. One endogenous fragment was measured only as a diagnostic biomarker.
    • small or imprecise: Only 31 cases and 31 controls, with a testing set of 10 per group.
    • abstract only: Only the PubMed abstract is available in the record. Methods, funding and conflicts are not described.
    • inappropriate population: Participants were pregnant women with or without preeclampsia, and no compound was administered to them, so the study is not relevant to the claims.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 23840341, abstract (sentences 5-7) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 23840341, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 23840341, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 23840341, abstract (sentence 2) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).